Laura Cove-Smith - Concepedia

Author

Laura Cove-Smith

University of Manchester

Also Known As

L Cove-Smith, L Cove‐Smith, L. Cove-Smith, L.S. Cove-Smith, Laura Cove-Smith, Laura Covesmith

Publications

514

Citations

H-Index

Concepts

All Affiliations

University of Manchester The Christie NHS Foundation Trust South Tees Hospitals NHS Foundation Trust Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori Hôpital Intercommunal de Créteil

About

Laura Cove-Smith is an author at University of Manchester specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	93
2	Pathology	3	3	81
3	Public Health	2	2	68
4	Immunology	2	2	24
5	Health Sciences	1	1	13

Laura Cove-Smith

Publications

378

Citations

H-Index

Page 1

	Year	Citations
Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial Marina Chiara Garassino, Julien Mazières, Martin Reck, Journal of Thoracic Oncology	2022	112
Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial Eric Lim, David Waller, Kelvin Lau, The Lancet Respiratory Medicine	2024	99
An Integrated Characterization of Serological, Pathological, and Functional Events in Doxorubicin-Induced Cardiotoxicity Laura Cove-Smith, Neil Woodhouse, Adam Hargreaves, Toxicological Sciences Cardiac MuscleHeart FailurePathologyCardiovascular ToxicityRat Model	2014	57
Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma Liezel Griffin, Laura Cove-Smith, Hana Alachkar, JAAD Case Reports	2018	49
Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index Ana Ortega-Franco, Clare Hodgson, H Raja, Targeted Oncology Prognostic BiomarkersMedicineReal-world DataImmunologyPathology	2022	13
Experience With the Routine Use of Electronic Patient-Reported Outcome Measures for Patients With Lung Cancer Cathryn Crockett, James Price, Mai Khanh Pham, JCO Clinical Cancer Informatics	2023	13
108MO Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6) M.C. Garassino, J. Mazieres, Martin Reck, Annals of Oncology Radiation MedicineOncologyRadiation TherapyCancer ManagementEfficacy Outcomes	2022	12
Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer—final analysis from the phase II PACIFIC-6 trial Marina Chiara Garassino, Jonathan Khalifa, Martin Reck, ESMO Open	2025	12
High-dose Interleukin 2-induced Myocarditis Shien Chow, Laura Cove-Smith, Matthias Schmitt, Journal of Immunotherapy Heart FailureHd-il2-related MyocarditisImmunologyPathologyAcute Myocardial Infarction	2014	11

Page 1